Laura Zink
Family · Nashville, TNNPI 1225766553
Payments from drug & device makers
Across 83 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$347
- Novo Nordisk$340
- Pfizer$262
- Lilly USA, LLC$166
- AbbVie$133
- Corcept Therapeutics$127
- plus $523 from 13 others
What the payments were for
- Food & beverage$1,898100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $347 |
| Novo Nordisk | 12 | $340 |
| Pfizer | 13 | $262 |
| Lilly USA, LLC | 8 | $166 |
| AbbVie | 6 | $133 |
| Corcept Therapeutics | 4 | $127 |
| Amgen | 5 | $117 |
| Idorsia Pharmaceuticals US Inc | 4 | $72 |
| Astellas Pharma US Inc | 2 | $53 |
| Bayer | 2 | $49 |
| Azurity Pharmaceuticals, Inc. | 2 | $47 |
| GSK | 2 | $42 |
| Exact Sciences | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Abbott | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,898 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 56 | $33,908 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $33,440 |
| Repatha SureclickEvolocumab | 30 | $17,175 |
| OzempicSemaglutide | 14 | $11,781 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $11,111 |
| TrulicityDulaglutide | 11 | $10,911 |
| MyrbetriqMirabegron | 11 | $5,688 |
| Pregabalin | 32 | $1,481 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,002 |
| Rosuvastatin Calcium | 65 | $838 |
| Metoprolol Succinate | 45 | $590 |
| Celecoxib | 18 | $581 |
| Azelastine Hcl | 13 | $408 |
| Fluticasone Propionate | 26 | $398 |
| Duloxetine Hcl | 18 | $396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $347 | $67,347109 claims |
| Novo NordiskOzempic | $340 | $11,78114 claims |
| GSKTrelegy Ellipta | $42 | $11,11111 claims |
| Lilly USA, LLCTrulicity | $166 | $10,91111 claims |
| Astellas Pharma US IncMyrbetriq | $53 | $5,68811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.
Other family in Nashville
- Tamera ThoenerNashville$254K
- Jennifer WilliamsNashville$213K
- Lori LankfordNashville$148K
- Melissa RikalNashville$144K
- Nicole DelliseNashville$67K
- Lesley BallanceNashville$63K
- Jeffrey WoodsNashville$38K
- Courtney HavillNashville$35K
- Collette UtleyNashville$28K
- Stacy BrownMt Juliet$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.